Brief: Aura Biosciences Says Belzupacap Sarotalocan Offers Favorable Safety Profile
03/10/2022 12:16
Oct 3 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES - BELZUPACAP SAROTALOCAN OFFERS FAVORABLE
SAFETY PROFILE
* AURA BIOSCIENCES INC - INTERIM DATA SHOWED A STATISTICALLY
SIGNIFICANT REDUCTION IN TUMOR GROWTH RATE AND A ROBUST TUMOR
CONTROL RESPONSE
Source text for Eikon: ID:nBw8KTFxDa
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs